Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities:
Net loss	$ (3,940)	$ (37,417)
Adjustments to reconcile net loss to cash used in operating activities:
Acquired in-process research and development		23,049
Depreciation and amortization	31	25
Stock-based compensation	1,038	1,298
Net unrealized loss (gain) on foreign currency transactions	159	(140)
Amortization of term loan discount and issuance costs	30	48
Amortization of investments, net	(296)	47
Deferred revenue	(2,370)
Changes in operating assets and liabilities:
Accounts receivable	(586)
Prepaid expenses and other current assets	(1,983)	(553)
Accounts payable	1,726	2,692
Accrued expenses	(1,771)	(1,218)
Right-of-use assets and lease liabilities, net	(33)	35
Net cash used in operating activities	(7,995)	(12,134)
Investing activities:
Purchases of property and equipment		(223)
Purchases of short-term investments	(37,181)	(14,962)
Maturities of short-term investments	12,000	2,500
Cash acquired in Bioniz acquisition		700
Net cash used in investing activities	(25,181)	(11,985)
Financing activities:
Principal repayments on notes payable	(1,429)
Net cash used in financing activities	(1,429)
Effect of exchange rate changes on cash and cash equivalents	1	(3)
Net decrease in cash and cash equivalents	(34,604)	(24,122)
Cash and cash equivalents at beginning of period	59,107	50,366
Cash and cash equivalents at end of period	$ 24,503	26,244
Supplemental disclosures of non-cash activities:
Fair value of Bioniz assets acquired		23,049
Issuance of common stock for Bioniz acquisition		(22,542)
Bioniz net liabilities assumed		507
Amounts included in accounts payable for purchases of property and equipment		$ 36